> top > docs > PubMed@pruas_18:32965395_en > annotations

PubMed@pruas_18:32965395_en JSONTXT

Annnotations TAB JSON ListView MergeView

ENG_NER_NEL

Id Subject Object Predicate Lexical cue
T11 229-237 MESH:D010361 denotes patients
T12 267-278 CHEBI:64360 denotes tocilizumab
T14 404-412 DOID:0080600 denotes COVID-19
T16 441-468 MESH:D016449 denotes randomized controlled trial
T17 503-514 CHEBI:64360 denotes tocilizumab
T19 570-578 MESH:D010361 denotes patients
T20 584-592 HP:0012826 denotes moderate
T21 596-602 HP:0012828 denotes severe
T22 603-611 DOID:0080600 denotes COVID-19
T24 736-744 CHEBI:82594 denotes ferritin
T25 761-768 CHEBI:24996 denotes lactate
T27 930-938 DOID:0080600 denotes COVID-19
T29 1102-1105 CHEBI:84123 denotes age
T3 44-48 CHEBI:50906 denotes role
T30 1163-1170 HP:0030645 denotes central
T31 1204-1210 MESH:D001938 denotes Brazil
T32 1360-1366 MESH:D016454 denotes review
T34 1587-1595 DOID:0080600 denotes COVID-19
T36 1596-1604 MESH:D010361 denotes patients
T4 44-48 MESH:D012380 denotes role
T5 56-63 DOID:4 denotes disease
T6 56-63 MESH:D004194 denotes disease
T7 64-72 HP:0012824 denotes severity
T8 76-84 MESH:D010361 denotes patients
T9 90-98 DOID:0080600 denotes COVID-19

test_lasige

Id Subject Object Predicate Lexical cue
T4 44-48 MESH:D012380 denotes role
T3 44-48 CHEBI:50906 denotes role
T6 56-63 MESH:D004194 denotes disease
T5 56-63 DOID:4 denotes disease
T7 64-72 HP:0012824 denotes severity
T8 76-84 MESH:D010361 denotes patients
T9 90-98 DOID:0080600 denotes COVID-19
T11 229-237 MESH:D010361 denotes patients
T12 267-278 CHEBI:64360 denotes tocilizumab
T14 404-412 DOID:0080600 denotes COVID-19
T16 441-468 MESH:D016449 denotes randomized controlled trial
T17 503-514 CHEBI:64360 denotes tocilizumab
T19 570-578 MESH:D010361 denotes patients
T20 584-592 HP:0012826 denotes moderate
T21 596-602 HP:0012828 denotes severe
T22 603-611 DOID:0080600 denotes COVID-19
T24 736-744 CHEBI:82594 denotes ferritin
T25 761-768 CHEBI:24996 denotes lactate
T27 930-938 DOID:0080600 denotes COVID-19
T29 1102-1105 CHEBI:84123 denotes age
T30 1163-1170 HP:0030645 denotes central
T31 1204-1210 MESH:D001938 denotes Brazil
T32 1360-1366 MESH:D016454 denotes review
T34 1587-1595 DOID:0080600 denotes COVID-19
T36 1596-1604 MESH:D010361 denotes patients

ENG_NER_NEL_mabarros

Id Subject Object Predicate Lexical cue
T11 229-237 MESH:D010361 denotes patients
T12 267-278 CHEBI:64360 denotes tocilizumab
T14 404-412 DOID:0080600 denotes COVID-19
T16 441-468 MESH:D016449 denotes randomized controlled trial
T17 503-514 CHEBI:64360 denotes tocilizumab
T19 570-578 MESH:D010361 denotes patients
T20 584-592 HP:0012826 denotes moderate
T21 596-602 HP:0012828 denotes severe
T22 603-611 DOID:0080600 denotes COVID-19
T24 736-744 CHEBI:82594 denotes ferritin
T27 930-938 DOID:0080600 denotes COVID-19
T3 44-48 CHEBI:50906 denotes role
T31 1204-1210 MESH:D001938 denotes Brazil
T32 1360-1366 MESH:D016454 denotes review
T34 1587-1595 DOID:0080600 denotes COVID-19
T36 1596-1604 MESH:D010361 denotes patients
T4 44-48 MESH:D012380 denotes role
T5 56-63 DOID:4 denotes disease
T6 56-63 MESH:D004194 denotes disease
T7 64-72 HP:0012824 denotes severity
T8 76-84 MESH:D010361 denotes patients
T9 90-98 DOID:0080600 denotes COVID-19

ENG_NER_NEL_pruas

Id Subject Object Predicate Lexical cue
T11 229-237 MESH:D010361 denotes patients
T12 267-278 CHEBI:64360 denotes tocilizumab
T14 404-412 DOID:0080600 denotes COVID-19
T16 441-468 MESH:D016449 denotes randomized controlled trial
T17 503-514 CHEBI:64360 denotes tocilizumab
T19 570-578 MESH:D010361 denotes patients
T20 584-592 HP:0012826 denotes moderate
T21 596-602 HP:0012828 denotes severe
T22 603-611 DOID:0080600 denotes COVID-19
T24 736-744 CHEBI:82594 denotes ferritin
T25 761-768 CHEBI:24996 denotes lactate
T27 930-938 DOID:0080600 denotes COVID-19
T3 44-48 CHEBI:50906 denotes role
T31 1204-1210 MESH:D001938 denotes Brazil
T32 1360-1366 MESH:D016454 denotes review
T34 1587-1595 DOID:0080600 denotes COVID-19
T36 1596-1604 MESH:D010361 denotes patients
T37 90-98 DOID:0080600 denotes COVID-19
T38 106-133 CHEBI:67079 denotes anti-inflammatory therapies
T39 351-365 MESH:D015850 denotes interleukin-6,
T4 44-48 MESH:D012380 denotes role
T40 404-412 HP:0033141 denotes COVID-19
T41 603-611 HP:0033141 denotes COVID-19
T42 930-938 HP:0033141 denotes COVID-19
T43 1587-1595 HP:0033141 denotes COVID-19
T44 186-219 GO:0002526 denotes uncontrolled inflammatory cascade
T45 90-98 MESH:D000086742 denotes COVID-19
T46 404-412 MESH:D000086742 denotes COVID-19
T47 603-611 MESH:D000086742 denotes COVID-19
T48 930-938 MESH:D000086742 denotes COVID-19
T49 1587-1595 MESH:D000086742 denotes COVID-19
T5 56-63 DOID:4 denotes disease
T50 707-725 MESH:D002097 denotes C reactive protein
T51 736-744 MESH:D005293 denotes ferritin
T52 1562-1583 GO:0006954 denotes inflammatory response
T6 56-63 MESH:D004194 denotes disease
T7 64-72 HP:0012824 denotes severity
T8 76-84 MESH:D010361 denotes patients
T9 90-98 HP:0033141 denotes COVID-19

ENG_NER_NEL_Diana

Id Subject Object Predicate Lexical cue
T11 229-237 MESH:D010361 denotes patients
T12 267-278 CHEBI:64360 denotes tocilizumab
T14 404-412 DOID:0080600 denotes COVID-19
T16 441-468 MESH:D016449 denotes randomized controlled trial
T17 503-514 CHEBI:64360 denotes tocilizumab
T19 570-578 MESH:D010361 denotes patients
T20 584-592 HP:0012826 denotes moderate
T21 596-602 HP:0012828 denotes severe
T22 603-611 DOID:0080600 denotes COVID-19
T24 736-744 CHEBI:82594 denotes ferritin
T25 761-768 CHEBI:24996 denotes lactate
T27 930-938 DOID:0080600 denotes COVID-19
T3 44-48 CHEBI:50906 denotes role
T31 1204-1210 MESH:D001938 denotes Brazil
T34 1587-1595 DOID:0080600 denotes COVID-19
T36 1596-1604 MESH:D010361 denotes patients
T4 44-48 MESH:D012380 denotes role
T5 56-63 DOID:4 denotes disease
T6 56-63 MESH:D004194 denotes disease
T7 64-72 HP:0012824 denotes severity
T8 76-84 MESH:D010361 denotes patients
T9 90-98 DOID:0080600 denotes COVID-19